Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study
Confirmatory Phase III Trial Misses Endpoint
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
